Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

Gov. Whitmer called on Michigan residents, businesses, schools, local governments and other organizations to join the tribute ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...